|1.||Handelsman, David J: 8 articles (01/2015 - 10/2003)|
|2.||Stener-Victorin, Elisabet: 8 articles (12/2014 - 11/2007)|
|3.||Mohler, James L: 8 articles (05/2014 - 01/2004)|
|4.||Yeap, Bu B: 6 articles (06/2015 - 11/2013)|
|5.||Titus, Mark A: 6 articles (05/2014 - 06/2005)|
|6.||Lin, Hung-Yun: 5 articles (11/2015 - 06/2005)|
|7.||Takahashi, Kota: 5 articles (01/2013 - 11/2004)|
|8.||Nishiyama, Tsutomu: 5 articles (01/2013 - 11/2004)|
|9.||Chang, Chawnshang: 5 articles (03/2012 - 06/2005)|
|10.||Bartsch, G: 5 articles (02/2008 - 04/2000)|
|1.||Prostatic Neoplasms (Prostate Cancer)
07/01/2005 - "This surprising finding suggests intracrine production of dihydrotestosterone and should be exploited for novel treatment of recurrent prostate cancer."
01/01/2014 - "Recent clinical studies have raised the clinically important question of the relationship between dihydrotestosterone (DHT) and prostate cancer (PCa) progression. "
09/01/2009 - "In the present study, we evaluated the biological significance of Prx1 in modulating dihydrotestosterone (DHT)-stimulated growth and AR target gene expression of prostate cancer cells. "
08/01/2004 - "We used oligonucleotide array technology to study the expression profiles of ARGs in LNCaP prostate cancer cells and identified 692 dihydrotestosterone-regulated genes. "
01/01/1988 - "The aim of the study was to provide an opportunity to detect the variation of dihydrotestosterone (DHT) in prostatic tissue on endocrine manipulations in phase III studies of metastatic prostatic cancer. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/01/2010 - "Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study."
11/01/1992 - "Many studies have intimated that the accumulation and hence elevation of dihydrotestosterone (DHT) in the human prostate may be the primary factor in the development of benign prostatic hyperplasia (BPH). "
06/01/1983 - "Previous studies have demonstrated that the 2-3--fold abnormal elevation in prostatic dihydrotestosterone (DHT) content characteristically associated with canine benign prostatic hyperplasia (BPH) is due to a shift in the overall balance in the complex metabolism of DHT in the gland itself [1, 2]. "
01/01/2015 - "Benign prostatic hyperplasia (BPH) is one of the common male diseases, which is provoked by dihydrotestosterone (DHT) and androgen signals. "
09/01/2010 - "Community dwelling men show a stepwise increase in benign prostatic hyperplasia risk with higher midlife serum dihydrotestosterone. "
10/01/2015 - "It may be similar to androgenic alopecia in men that is caused by the effect of dihydrotestosterone (DHT). "
06/15/2015 - "Androgenetic alopecia involves the action of dihydrotestosterone (DHT) on dermal papilla cells (DPCs) that line the base of the hair follicle. "
06/01/2015 - "suspensa), on entry into catagen induced by dihydrotestosterone (DHT) in an androgenic alopecia mouse model. "
08/01/2014 - "Dihydrotestosterone is the most influential androgen and seems to play a very important role in the pathogenesis of androgenetic alopecia. "
08/01/2014 - "Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia."
03/01/1988 - "Three tumors were subjected to in vitro growth studies in varying concentrations of dihydrotestosterone (DHT). "
10/01/2013 - "Positron emission tomography/computed tomography imaging was conducted to monitor [(18)F]fluoro-α-dihydrotestosterone (FDHT) binding to AR in tumors before and during treatment. "
07/01/2013 - "This TCM-induced cell growth in MECs was enhanced by the treatment of prostatic tumor cells with dihydrotestosterone (DHT). "
10/01/2009 - "Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents."
10/01/2008 - "When inoculated subcutaneously into dihydrotestosterone-supplemented castrated nude mice, large tumors formed rapidly in 20 of 20 mice, whereas no tumors developed in mice without circulating dihydrotestosterone. "
|5.||Androgen-Insensitivity Syndrome (Testicular Feminization)
01/01/1986 - "Autoradiographic studies with 3H dihydrotestosterone in the brain of sex reversed mice, heterozygous for androgen insensitive testicular feminization (Tfm). "
08/18/1977 - "Dihydrotestosterone binding studies in skin fibroblasts demonstrated two genetic variants similar to those reported in complete androgen insensitivity syndrome. "
01/01/2002 - "Androgen insensitivity syndromes (AIS) result from the incapacity for T and dihydrotestosterone to virilize male embryos and is mainly attributable to molecular defects of the AR gene. "
03/01/2001 - "Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5alpha dihydrotestosterone availability."
01/01/1986 - "Specific binding sites for 3H dihydrotestosterone are demonstrated by autoradiography in brain nuclei of sex reversed mice heterozygous for testicular feminization (Tfm) which are phenotypically intersexes with testes and accessory sex glands that consist of a mosaic of androgen insensitive Tfm cells which lack specific dihydrotestosterone binding and androgen sensitive normal cells. "
|6.||Androgen Receptors (Androgen Receptor)
|7.||Androstenedione (4 Androstene 3,17 dione)
|9.||Cholestenone 5 alpha-Reductase (5 alpha-Reductase)
|10.||Prostate-Specific Antigen (Semenogelase)
|1.||Drug Therapy (Chemotherapy)